Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.

A user is frustrated that their dermatologist requires blood and sperm tests before prescribing oral finasteride, despite already taking oral minoxidil. They prefer oral medication over topical treatments due to sensory issues and are considering asking their GP for a finasteride prescription or seeking alternatives online.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

The conversation discusses the potential benefits of creating a hydrophobic version of finasteride to reduce systemic side effects while maintaining scalp health. It compares this idea to fluridil, which is designed to be hydrophobic and has less systemic absorption.

JXL069, also known as PP405, did not lead to hair regrowth after a year of testing. The lack of results may be due to formulation issues, leading to a final attempt with an improved vehicle.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

The conversation discusses a community called PHG, which focuses on experimental hair loss treatments and scientific approaches to hair regrowth. It mentions treatments like Minoxidil, finasteride, and RU58841, and highlights interest in new treatments like Setipripant, Histogen, and Replicel.

Human pluripotent stem cells have been used to create hair and skin, potentially offering a new solution for baldness. A user also mentioned starting finasteride but experiencing unexpected hair thinning.

The conversation is about using microneedling for hair loss treatment, including questions on disinfection and post-treatment care. The user mentions using oral minoxidil and finasteride, and considering dutasteride.

The conversation discusses experimenting with microneedling for hair loss, with OP considering using a 3mm derma-stamp. Other users advise against going beyond 1.5mm to avoid damage.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

The conversation discusses skepticism and diminishing excitement around the hair loss treatment PP405 due to unclear trial results. It also mentions other treatments like finasteride, minoxidil, VDPHL01 (extended-release minoxidil), and GT20026 as potential options for hair loss management.

The user experienced increased hair shedding after switching from finasteride to dutasteride, despite lifestyle improvements and additional treatments like oral minoxidil and PRP. They are concerned about persistent shedding, changes in hormone levels, and potential chronic telogen effluvium, and are considering a scalp biopsy for further investigation.

The ineffectiveness of Strut Health's dutasteride capsules, which are filled with raw powder instead of liquid and don't contain any buffering agents that would allow for absorption into the bloodstream. It is suggested to use other brands of liquid-filled dutasteride capsules for better results.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

A user shared their 6-month progress using 1ml of Kirkland minoxidil daily and weekly 1mm dermarolling, noting no side effects and minimal shedding. They plan to consider finasteride or dutasteride after midterms, attributing hair loss to genetics.

A 27-year-old male experienced significant hair shedding after switching from minoxidil to oral finasteride for hair loss treatment. Despite being healthy and using finasteride for nearly 100 days, he noticed increased shedding and is seeking support and success stories from others.

The user reported positive results in hair density and skin improvement using a combination of oral Minoxidil, Finasteride, and subcutaneous GHK-Cu. They experienced less shedding with oral Minoxidil compared to topical and noted significant skin benefits from GHK-Cu.

Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

The user is concerned about losing hair after a transplant and questions whether using topical finasteride instead of oral is effective. The consensus suggests oral finasteride is more effective, while topical may not penetrate the scalp well enough.

A new "third cell" discovery in Japan could be key to fully regenerating hair follicles, with human trials possibly starting in 2027-2028. AI is expected to accelerate medical discoveries, potentially leading to a hair loss cure within a few years.

The conversation is about purchasing dutasteride capsules from India and concerns about high temperatures affecting their efficacy. Users suggest that medicines are stored in cool conditions and recommend gel capsules over tablets.

The user is experimenting with a homemade topical dutasteride formulation to reduce hair loss while minimizing systemic absorption, using MCT oil, almond oil, vitamin E, tea tree oil, and lavender oil. They are monitoring hair growth and side effects, particularly focusing on sexual health, and are open to feedback on their approach.

A user shared their positive experience with Roots by GA, a company that creates personalized hair loss treatments based on DNA analysis, which confirmed their inability to tolerate finasteride. The user is satisfied with their progress 30 days after a hair transplant and the customized formula they received.

A fake hair loss product called "PP405" is being humorously discussed, with users joking about its effectiveness and availability on resale websites. The consensus is that it's a scam, with some users sarcastically claiming miraculous results.

PP405 may encourage earlier hair growth and slightly increase visible hair count but does not reverse hair follicle miniaturization in male pattern baldness. It does not address damage to the dermal papilla or broken Wnt signaling.

The conversation discusses an experiment involving hair loss treatments, including the use of Verteporfin, KY19382, dutasteride, oral and topical minoxidil, AHK-Cu, and microneedling. The experiment aims to test the effectiveness of these treatments in promoting hair growth and healing without scarring, with updates planned every few months.

Scientists have grown natural-looking hair from stem cells, potentially revolutionizing hair growth treatments. Concerns include cost, DHT resistance, and the need for future procedures.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.